Short-term intravenous bisphosphonates in prevention of postmenopausal bone loss

Journal of Bone and Mineral Research

Volumn 12, Issue 1, 1997, Pages 103-110

  Heikkinen, Jorma E ^a   Selander, Katri S ^b   Laitinen, Kalevi ^c   Arnala, Ilkka ^d   Väänänen, H Kalervo ^b  

^a OULU DEACONESS INSTITUTE   (Finland)

^b UNIVERSITY OF OULU   (Finland)

^c Oy Leiras Finland Ab   (Finland)

^d UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; COLLAGEN TYPE 1; ETIDRONIC ACID; HYDROXYPROLINE; OSTEOCALCIN; PROCOLLAGEN;

ADULT; ARTICLE; BONE ATROPHY; BONE DENSITY; BONE METABOLISM; BONE MINERAL; BONE TURNOVER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FEMUR NECK; HUMAN; HUMAN TISSUE; LUMBAR SPINE; MAJOR CLINICAL STUDY; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIAL;

BONE DENSITY; CALCITRIOL; CALCIUM; CLODRONIC ACID; COLLAGEN; COLLAGEN TYPE I; CREATININE; DENSITOMETRY, X-RAY; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ETIDRONIC ACID; FEMALE; FEMUR NECK; FOLLOW-UP STUDIES; HUMANS; HYDROXYPROLINE; INJECTIONS, INTRAVENOUS; LONGITUDINAL STUDIES; LUMBAR VERTEBRAE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PEPTIDE FRAGMENTS; PEPTIDES; PROCOLLAGEN; PROSPECTIVE STUDIES;

EID: 0031019021     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.1997.12.1.103     Document Type: Article

References (32)

1. Fleisch H 1991 Bisphosphonates: Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease. Drugs 6:919-944.
2. Lombardi A, Santora AC 1993 Clinical trials with bisphosphonates. Bone Miner 22 (Suppl):S59-S70.
3. 14C-clodronate in mice and rats. Pharmacol Toxicol 62:51-53.
4. Geddes AD, D'Souza SM, Ebetino FH, Ibbotson KJ 1994 Bisphosphonates: Structure-activity relationships and therapeutic implications. In: Heershce JNM, Kanis JA (eds.) Bone and Mineral Res, Vol 8. Amsterdam: Elsevier Science BV, pp. 265-306.
5. Flanagan AM, Chambers TJ 1991 Inhibition of bone resorption by bisphosphonates: Interactions between bisphosphonates, osteoclasts, and bone. Calcif Tissue Int 49:407-415.
6. Sato M, Grasser W, Endo N, Akins R, Simmons H, Thompson DD, Golub E, Rodan GA 1991 Bisphosphonate action: Alendronate localization in rat bone and effects of osteoclast ultrastructure. J Clin Invest 88:2095-2105.
7. Selander KS, Härkönen PL, Mönkkönen J, Hannuniemi R, Väänänen HK 1995 The mode of death induced by clodronate in isolated osteoclasts is apoptosis (abstract). Calcif Tissue Int 56:450.
8. Sahni M, Guenther HL, Fleisch H, Collin P, Martin TJ 1993 Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. J Clin Invest 91:2002-2011.
9. Reginster JY, Lecart MP, Deroisy R, Sarlet N, Denis D, Ethgen D, Collette J, Franchimont P 1989 Prevention of postmenopausal bone loss by tiludronate. Lancet II (8678/79):1469-1471.
10. Watts NB, Harris ST, Genant HK, Wasnich RD, Miller PD, Jackson RD, Licata AA, Ross P, Woodson III GC, Yanover MJ, Mysiw WJ, Kohse L, Rao MB, Steiger P, Richmond B, Chesnut III CH 1990 Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. New Engl J Med 323:73-79.
11. Evans RA, Somers NM, Dunstan CR, Royle H, Kos S 1993 The effect of low-dose cyclical etidronate and calcium on bone mass in early postmenopausal women. Osteoporosis Int 3:71-75.
12. Passeri M, Baroni MC, Pedrazzoni M, Pioli G, Barvagallo M, Costi D, Biondi M, Girasole G, Arlunno B, Palummeri E 1991 Intermittent treatment with intravenous 4-amino-l-hydroxybutylidene-1,1-bisphosphonate (AHBuBP) in the therapy of post-menopausal osteoporosis. Bone Miner 15:237-248.
13. Riggs BL, Melton LJ 1992 The prevention and treatment of osteoporosis. New Engl J Med 327:620-627.
14. Filipponi P, Pedetti M, Fedeli L, Cini L, Palumbo R, Boldrini S, Massoni C, Cristallini S 1995 Cyclical clodronate is effective in preventing postmenopausal bone loss: A comparative study with transcutaneous hormone replacement therapy. J Bone Miner Res 5:697-703.
15. Liberman UA, Wiss SR, Bröll J, Minne HW, Quan H, Bell NH, Rodriquez-Portales J, Downs RW, Dequeker J, Favus M, Seeman E, Recker RR, Capizzi T, Santora AC, Lombardi A, Shah RV, Hirsch LJ, Karpf DB 1995 Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. New Engl J Med 333:1437-1433.
16. Elomaa I, Blomqvist C, Gröhn P, Porkka L, Kairento A-L, Selander K, Lamberg-Allardt C, Holmström T 1983 Long-term controlled trial with diphosphonate in patients with osteolytic bone metastases. Lancet I (8317):146-148.
17. Yates AJ, Percival RC, Gray RE, Atkins RM, Urwin GH, Hamdy NA, Preston CJ, Beneton MN, Russell RG, Kanis JA 1985 Intravenous clodronate in the treatment and retreatment of Paget's disease of bone. Lancet II (8444):1474-1477.
18. Lahtinen R, Laakso M, Palva I, Virkkunen P, Elomaa I 1992 Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Lancet II (8827):1049-1052.
19. Giannini S, D'Angelo A, Malvasi L, Castrignano R, Pati T, Tronca R, Liberto L, Nobile M, Crepaldi G 1993 Effects of one-year cyclical treatment with clodronate on postmenopausal bone loss. Bone 14:137-141.
20. Plosker GL, Goa KL 1994 Clodronate: A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs 47:945-982.
21. Adami S, Bhalla AK, Dorizzi R, Montesanti F, Rosini S, Salvagno G, Locascio V 1987 The acute-phase response after bisphosphonate administration. Calcif Tissue Int 41:326-331.
22. Schweizer DH, Zwinderman AH, Vermeij P, Bijvoet OLM, Papapoulos S 1995 Improved treatment of Paget's disease with dimethylaminohydroxypropylidene bisphosphonate. J Bone Miner Res 8:175-182.
23. Ernst DS, MacDonald RN, Paterson AH, Jensen J, Brasher P, Bruera E A 1992 Double-blind, crossover trial of intravenous clodronate in metastatic bone pain. J Pain Symptom Manage 1:4-11.
24. Kylmälä T, Tammela TL, Lindholm TS, Seppqänen J 1994 The effect of combined intravenous and oral clodronate treatment on bone pain in patients with metastatic prostate cancer. Ann Chir Gynaecol 83:316-319.
25. O'Rourke NP, McCloskey EV, Vasikaran S, Eyres K, Fern D, Kanis JA 1993 Effective treatment of malignant hyprecalcaemia with a single intravenous infusion of clodronate. Br J Cancer 67:560-563.
26. Adami S, Zamberlan N, Mian M, Dorizzi R, Rossini M, Braga B, Gatti D, Bertoldo F, Locascio V 1994 Duration of the effects of intravenous alendronate in postmenopausal women and in patients with primary hyperparathyreoidism and Paget's disease of bone. Bone Miner 25:75-82.
27. O'Doherty DP, McCloskey EV, Vasikaran S, Khan S, Kanis JA 1995 The effects of intravenous alendronate in Paget's disease of bone. J Bone Miner Res 10:1094-1100.
28. Malluche HH, Faugere MC 1986 Atlas of Mineralized Bone Histology. Karger, New York, NY, U.S.A.
29. Malluche HH, Sherman D, Meyer W, Massry SG 1982 A new semiautomatic method for quantitative static and dynamic bone histology. Calcif Tissue Int 34:439-448.
30. Parfitt AM 1988 Bone histomorphometry: Standardization of nomenclature, symbols and units (Summary of proposed system). Bone 9:67-69.
31. Harris ST, Gertz BJ, Genant HK, Eyre DR, Survill TT, Ventura JN, DeBrock J, Ricerca E, Chesnut III CH 1993 The effect of short-term treatment with alendronate on vertebral density and biochemical markers of bone remodeling in early post-menopausal women. J Clin Endocrinol Metab 6:1399-1406.
32. Risteli J, Elomaa I, Niemi S, Risteli L 1993 Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: A new serum marker of bone collagen degradation. Clin Chem 39:635-640.